Last reviewed · How we verify
Intramuscular ephedrine
Intramuscular ephedrine, marketed by Hospital de Base, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Intramuscular ephedrine |
|---|---|
| Sponsor | Hospital de Base |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intramuscular Ephedrine in the Prevention of Hypotension in Patients Undergoing Spinal Anesthesia (PHASE4)
- Oxytocin And Uterotonic Agent Use For Cesarean Delivery (PHASE4)
- Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section (PHASE2)
- Effects of Systemic or Adjunct Tramadol Addition to Lidocaine Used for IVRA in Patients Undergoing Hand Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |